Perceived safety and efficacy of neuromuscular blockers for acute respiratory distress syndrome among medical intensive care unit practitioners: A multicenter survey

Journal of Critical Care

Volumn 38, Issue , 2017, Pages 278-283

  Torbic, Heather ^a   Bauer, Seth R ^a   Personett, Heather A ^b   Dzierba, Amy L ^c   Stollings, Joanna L ^d   Ryder, Lindsay P ^e   Daniels, Craig E ^b   Caples, Sean M ^b   Frazee, Erin N ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Acute respiratory distress syndrome; Neuromuscular blocking agent; Pharmacist; Prescriber; Survey

Indexed keywords

NEUROMUSCULAR BLOCKING AGENT; PROSTAGLANDIN;

ADULT RESPIRATORY DISTRESS SYNDROME; ANALGESIC ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONSCIOUSNESS; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FELLOW; HEALTH CARE SURVEY; HEALTH PRACTITIONER; HUMAN; HUMAN EXPERIMENT; INTENSIVIST; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MEDICAL INTENSIVE CARE UNIT; MULTICENTER STUDY; NURSE PRACTITIONER; PERCEPTION; PHARMACIST; PHYSICIAN ASSISTANT; PROFESSIONAL KNOWLEDGE; PROSPECTIVE STUDY; TERTIARY CARE CENTER; TITRIMETRY; TRANQUILIZING ACTIVITY; ARTIFICIAL VENTILATION; CLINICAL COMPETENCE; CROSS-SECTIONAL STUDY; HEALTH PERSONNEL ATTITUDE; INTENSIVE CARE; INTENSIVE CARE UNIT; PHYSICIAN; PROCEDURES; QUESTIONNAIRE; RESPIRATORY DISTRESS SYNDROME, ADULT; SAFETY;

ATTITUDE OF HEALTH PERSONNEL; CLINICAL COMPETENCE; CRITICAL CARE; CROSS-SECTIONAL STUDIES; HUMANS; INTENSIVE CARE UNITS; NEUROMUSCULAR BLOCKING AGENTS; NURSE PRACTITIONERS; PHARMACISTS; PHYSICIAN ASSISTANTS; PHYSICIANS; PROSPECTIVE STUDIES; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT; SAFETY; SURVEYS AND QUESTIONNAIRES; TERTIARY CARE CENTERS;

EID: 85013659586     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2016.11.040     Document Type: Article

References (29)

1. [1] Rubenfeld, G.D., Caldwell, E., Peabody, E., Weaver, J., Martin, D.P., Neff, M., et al. Incidence and outcomes of acute lung injury. N Engl J Med 353:16 (2005), 1685–1693.
2. [2] Herridge, M.S., Cheung, A.M., Tansey, C.M., Matte‐Martyn, A., Diaz‐Granados, N., Al‐Saidi, F., et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 348 (2003), 683–693.
3. [3] Herridge, M.S., Tansey, C.M., Matte, A., Tomlinson, G., Diaz‐Granados, N., Cooper, A., et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med 364:14 (2011), 1293–1304.
4. [4] Slutsky, A.S., Neuromuscular blocking agents in ARDS. N Engl J Med 363:12 (2010), 1176–1180.
5. [5] Gattinoni, L., Marini, J.J., Prone positioning and neuromuscular blocking agents are part of standard care in severe ARDS patients: we are not sure. Intensive Care Med 41 (2015), 2201–2203.
6. [6] Hraiech, S., Forel, J.M., Papazian, L., The role of neuromuscular blockers in ARDS: benefits and risks. Curr Opin Crit Care 18 (2012), 495–502.
7. [7] Arroliga, A.C., Thompson, B.T., Ancukiewicz, M., Gonzales, J.P., Guntupalli, K.K., Park, P.K., et al. Use of sedatives, opioids, and neuromuscular blocking agents in patients with acute lung injury and acute respiratory distress syndrome. Crit Care Med 36:4 (2008), 1083–1088.
8. [8] Bellani, G., Laffey, J.G., Pham, T., Fan, E., Brochard, L., Esteban, A., et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 315:8 (2016), 788–800.
9. [9] Gainnier, M., Roch, A., Forel, J.M., Thirion, X., Arnal, J.M., Donati, S., et al. Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome. Crit Care Med 32:1 (2004), 113–119.
10. [10] Forel, J.M., Roch, A., Marin, V., Michelet, P., Demory, D., Blache, J.L., et al. Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. Crit Care Med 34:11 (2006), 2749–2757.
11. [11] Papazian, L., Forel, J.M., Gacouin, A., Penot-Ragon, C., Perrin, G., Loundou, A., et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 363:12 (2010), 1107–1116.
12. [12] Murray, M.J., Cowen, J., DeBlock, H., Erstad, B., Gray, A.W. Jr., Tescher, A.N., et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med 30:1 (2002), 142–156.
13. [13] Wagner, B.K., Zavotsky, K.E., Sweeney, J.B., Palmeri, B.A., Hammond, J.S., Patient recall of therapeutic paralysis in a surgical critical care unit. Pharmacotherapy 18:2 (1998), 358–363.
14. [14] Ballard, N., Robley, L., Barrett, D., Fraser, D., Mendoza, I., Patients' recollections of therapeutic paralysis in the intensive care unit. Am J Crit Care 15:1 (2006), 86–94.
15. [15] Johnson, K.L., Cheung, R.B., Johnson, S.B., Roberts, M., Niblett, J., Manson, D., Therapeutic paralysis of critically ill trauma patients: perceptions of patients and their family members. Am J Crit Care 8:1 (1999), 490–498.
16. [16] Arbour, R., Using bispectral index monitoring to detect potential breakthrough awareness and limit duration of neuromuscular blockade. Am J Crit Care 13 (2004), 66–73.
17. [17] Rhoney, D.H., Murry, K.R., National survey of the use of sedating drugs, neuromuscular blocking agents, and reversal agents in the intensive care unit. J Intensive Care Med 18 (2003), 139–145.
18. [18] Frazee, E.N., Personett, H.A., Bauer, S.R., Dzierba, A.L., Stollings, J.L., Ryder, L.P., et al. Intensive care nurses' knowledge about use of neuromuscular blocking agents in patients with respiratory failure. Am J Crit Care 24 (2015), 431–439.
19. [19] Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., Conde, J.G., Research Electronic Data Capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:2 (2009), 377–381.
20. [20] ISMP, ISMP list of high-alert medications in acute care settings. https://www.ismp.org/tools/institutionalhighAlert.asp;, 2014 [accessed 01.07.16].
21. [21] Foster, J.G., Kish, S.K., Keenan, C.H., A national survey of critical care nurses' practices related to administration of neuromuscular blocking agents. Am J Crit Care 10:3 (2001), 139–145.
22. [22] Strange, C., Vaughan, L., Franklin, C., Johnson, J., Comparison of train-of-four and best clinical assessment during continuous paralysis. Am J Resp Crit Care Med 156 (1997), 1556–1561.
23. [23] Rudis, M.I., Sikora, C.A., Angus, E., Peterson, E., Popovich, J., Hyzy, R., et al. A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med 25:4 (1997), 575–583.
24. [24] Baumann, M.H., McAlpin, B.W., Brown, K., Patel, P., Ahmad, I., Stewart, R., et al. A prospective randomized comparison of train-of-four monitoring and clinical assessment during continuous ICU cisatracurium paralysis. Chest 126:4 (2004), 1267–1273.
25. [25] Lagneau, F., D'Honneur, G., Plaud, B., Mantz, J., Gillart, T., Duvaldestin, P., et al. A comparison of two depths of prolonged neuromuscular blockade induced by cisatracurium in mechanically ventilated critically ill patients. Intensive Care Med 28:12 (2002), 1735–1741.
26. [26] Bein, T., Grasso, S., Moerer, O., Quintel, M., Guerin, C., Deja, M., et al. The standard of care of patients with ARDS: ventilator settings and rescue therapies for refractory hypoxemia. Intensive Care Med 42 (2016), 699–711.
27. [27] Alhurani, R.E., Oeckler, R.A., Franco, P.M., Jenkins, S.M., Gajic, O., Pannu, S.R., Refractory hypoxemia and use of rescue strategies: a United States national survey of adult intensivists. Ann Am Thorac Soc, 2016 [Epub ahead of print].
28. [28] Claesson, J., Freundlich, M., Gunnarsson, I., Laake, J.H., Møller, M.H., Vandvik, P.O., et al. Scandinavian clinical practice guideline on fluid and drug therapy in adults with acute respiratory distress syndrome. Acta Anaesthesiol Scand 60 (2016), 697–709.
29. [29] ClinicalTrials.Gov, Reevaluation of systemic early neuromuscular blockade (ROSE). https://clinicaltrials.gov/ct2/show/NCT02509078;, 2016 [accessed 06.24.16].